Teva Pharmaceutical Industries Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 1 sell rating, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Teva Pharmaceutical Industries stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View analyst ratings for Teva Pharmaceutical Industries or view top-rated stocks.

Wall Street analysts have given Teva Pharmaceutical Industries a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Teva Pharmaceutical Industries wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Teva Pharmaceutical Industries saw a decrease in short interest in March. As of March 31st, there was short interest totaling 25,040,000 shares, a decrease of 31.2% from the March 15th total of 36,370,000 shares. Based on an average trading volume of 9,260,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 2.3% of the company's shares are sold short.
View Teva Pharmaceutical Industries' Short Interest.

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its quarterly earnings results on Wednesday, April, 28th. The company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.08. The business earned $3.98 billion during the quarter, compared to analyst estimates of $4.04 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 19.32% and a negative net margin of 24.17%. Teva Pharmaceutical Industries's revenue for the quarter was down 8.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.76 EPS.
View Teva Pharmaceutical Industries' earnings history.

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TEVA stock has increased by 17.6% and is now trading at $10.60.
View which stocks have been most impacted by COVID-19.

Teva Pharmaceutical Industries updated its FY 2021 earnings guidance on Wednesday, May, 5th. The company provided EPS guidance of 2.500-2.700 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.610. The company issued revenue guidance of $16.40 billion-$16.80 billion, compared to the consensus revenue estimate of $16.68 billion.

11 equities research analysts have issued 12-month price targets for Teva Pharmaceutical Industries' shares. Their forecasts range from $8.00 to $16.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $11.78 in the next twelve months. This suggests a possible upside of 11.1% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries or view top-rated stocks among Wall Street analysts.

158 employees have rated Teva Pharmaceutical Industries CEO Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among Teva Pharmaceutical Industries' employees.

Some companies that are related to Teva Pharmaceutical Industries include Alexion Pharmaceuticals (ALXN), Astellas Pharma (ALPMY), BeiGene (BGNE), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), Genmab A/S (GMAB), Genmab A/S (GNMSF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Horizon Therapeutics Public (HZNP), CureVac (CVAC), UCB (UCBJF), Catalent (CTLT), Elanco Animal Health (ELAN) and Alnylam Pharmaceuticals (ALNY).
View all of TEVA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.84%), Migdal Insurance & Financial Holdings Ltd. (1.81%), Menora Mivtachim Holdings LTD. (1.50%), Capital International Investors (1.34%), Clal Insurance Enterprises Holdings Ltd (1.32%) and Phoenix Holdings Ltd. (1.06%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Rosemary A Crane and Sol J Barer.
View institutional ownership trends for Teva Pharmaceutical Industries.

TEVA stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Commonwealth of Pennsylvania Public School Empls Retrmt SYS, Capital International Investors, Credit Suisse AG, Russell Investments Group Ltd., Northern Trust Corp, Allianz Asset Management GmbH, and Bank of Montreal Can. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include David Matthew Stark, Mark Sabag, Richard Daniell, and Rosemary A Crane.
View insider buying and selling activity for Teva Pharmaceutical Industries or view top insider-selling stocks.

TEVA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Phoenix Holdings Ltd., Eversept Partners LP, Menora Mivtachim Holdings LTD., Banque Pictet & Cie SA, Pictet North America Advisors SA, Private Management Group Inc., and Dimensional Fund Advisors LP.
View insider buying and selling activity for Teva Pharmaceutical Industries or or view top insider-buying stocks.

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TEVA stock can currently be purchased for approximately $10.60.

Teva Pharmaceutical Industries has a market capitalization of $11.58 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis.

Teva Pharmaceutical Industries employs 37,100 workers across the globe.

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

Teva Pharmaceutical Industries is headquartered at 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]